McKesson Corporation (MCK)
| Market Cap | 30.96B |
| Revenue (ttm) | 237.62B |
| Net Income (ttm) | -4.18B |
| Shares Out | 159.50M |
| EPS (ttm) | -25.42 |
| PE Ratio | n/a |
| Forward PE | 10.20 |
| Dividend | $1.66 |
| Dividend Yield | 0.85% |
| Trading Day | April 20 |
| Last Price | $194.53 |
| Previous Close | $193.69 |
| Change ($) | 0.84 |
| Change (%) | 0.43% |
| Day's Open | 193.03 |
| Day's Range | 192.78 - 195.28 |
| Day's Volume | 512,735 |
| 52-Week Range | 124.38 - 198.43 |
Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2021 financial results after market close on Thursday, May 6, 2021. The company will host a live w...
Investors may want to consider the following securities as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future earnings are based on data...
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tesla, BlackBerry, McCormick and U.S. Steel were our top stock trades for Wednesday. Let's get a look at some of the charts.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
IRVING, Texas--(BUSINESS WIRE)--For the fifth consecutive year, McKesson has received approval from CMS to participate in the Merit-based Incentive Payment System (MIPS) as a QCDR.
IRVING, Texas--(BUSINESS WIRE)--McKesson launches ScriptPAS, an offering designed to help Medically Integrated Dispensing-equipped practices provide quicker access to care.
IRVING, Texas--(BUSINESS WIRE)--McKesson announces a collaboration with Vanderbilt Health Rx Solutions (VHRxS), a national leader in specialty pharmacy strategy and implementation.
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
McKesson (MCK) reported earnings 30 days ago. What's next for the stock?
A client asked whether there is a difference in our sell discipline between high- and low-growth companies.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
McKesson Corporation (MCK) CEO Brian Tyler on Q3 2021 Results - Earnings Call Transcript
The COVID-19 pandemic served as a tailwind for the big healthcare supply chain management company.
McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
McKesson (MCK) delivered earnings and revenue surprises of 11.38% and 1.16%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of McKesson Corp. rose 0.7% in premarket trading Tuesday, after the health care supply and retail pharmacy company reported a fiscal third-quarter loss of more than $6 billion as a result of an o...
Shares of McKesson (NYSE:MCK) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 20.73% over the past year to $4.60, which beat the est...
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) today reported results for the third quarter ended December 31, 2020. Fiscal 2021 Third-Quarter Result Summary Third-Quarter Year-to...
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 42 cents per share of common stock. The dividend will be payable on Ap...
McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
McKesson's poor capital allocation policy results in an ineffective use of its generated free cash flow. Cash flow generated is being deployed on low return acquisitions or share buybacks in an inadequa...
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
MCK vs. CNMD: Which Stock Is the Better Value Option?
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2021 financial results before market open on Tuesday, February 2, 2021. The company will host a live...
Here we discuss five GARP stocks, TAP, OMI, TD, MCK and HMC, which while trading cheap at this moment, are generating robust growth rates on strong fundamentals.
As I stated last week, the healthcare sector is one of my favorite sectors to find recession proof companies. Consumers will, to the best of their abilities, seek out treatments for what ails them even ...
McKesson Corp., the giant health care distributor selected by the U.S. government to manage logistics for the COVID-19 vaccine immunization campaign, on Sunday began pushing out millions of doses of Mod...
IRVING, Texas--(BUSINESS WIRE)--McKesson Fills Initial Government Orders for Moderna's COVID-19 Vaccine
Optimism on the progress of stimulus talks sent markets to more mild gains. After markets closed at record highs on Thursday, stimulus hopes sent markets higher again.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.
MCK vs. WST: Which Stock Is the Better Value Option?
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Let's see if McKesson Corp (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
One medical distribution company has been through this before.
About MCK
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other spe... [Read more...]
| Industry Medical Distribution | Founded 1833 |
| CEO Brian Tyler | Employees 80,000 |
| Stock Exchange NYSE | Ticker Symbol MCK |
Financial Performance
In 2019, McKesson's revenue was $231.05 billion, an increase of 7.81% compared to the previous year's $214.32 billion. Earnings were $900.00 million, an increase of 2,547.06%.
Analyst Forecasts
According to 19 analysts, the average rating for McKesson stock is "Buy." The 12-month stock price forecast is 219.07, which is an increase of 12.62% from the latest price.